romidepsin

Romidepsin, a selective inhibitor of histone deacetylase, is utilized for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have undergone prior systemic therapy. It was approved in the United States in 2009.

FK228, also referred to as FR901228, depsipeptide, NSC630176, or Romidepsin, was initially discovered as an antitumor antibiotic derived from the fermentation broth of Chromobacterium violaceum No. 968.

Bexarotene, a retinoid medication, is prescribed to individuals with cutaneous T-cell lymphoma (CTCL), a type of skin cancer, who have not responded to other treatments. It functions by inhibiting the proliferation of cancer cells.

Mycosis fungoides is the most prevalent variation of cutaneous T-cell lymphoma, a type of blood cancer. This form of cancer occurs when T cells, a type of white blood cell, become cancerous and typically affects the skin, leading to various types of skin lesions.

HDAC inhibition alters the ratio of pro- and anti-apoptotic proteins, leading to the death of tumor cells. By inhibiting HDAC, the intrinsic and extrinsic pathways of apoptosis are activated, resulting in the upregulation of proapoptotic genes such as Bmf and Bim, as well as TRAIL and DR5.

The structure of romidepsin has been determined to be a caged bicyclic depsipeptide using NMR spectroscopy and X-ray crystallography. It is a stable prodrug that, when taken up by the cell, undergoes reduction by glutathione to form a monocyclic dithiol.

Bristol Myers Squibb has decided to withdraw the indication for Romidepsin in the treatment of relapsed/refractory peripheral T-cell lymphoma due to the lack of clinical benefit.

During phase II studies, romidepsin demonstrated an overall response rate of 25-44% in patients with relapsed or refractory PTCL. This response rate included a complete response rate of 15-23%.

Clinical data
Trade names: Istodax
Other names: FK228; FR901228; Istodax
MedlinePlus: a610005
License data: US FDA: Romidepsin

Istodax (romidepsin) for Injection is a medication that inhibits histone deacetylase (HDAC) and is prescribed for the treatment of cutaneous T-cell lymphoma (CTCL), a type of lymphoma that affects the skin.

The FDA granted approval on June 16, 2011 for Celgene’s new drug application (NDA) 22393 for ISTODAX (romidepsin) for injection, 10 mg, to be used in the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have undergone at least one prior therapy. This approval falls under the Agency’s accelerated approval process.

The suggested amount of romidepsin to be given is 14 mg/m2 through an intravenous route, lasting for 4 hours. This should be done on days 1, 8, and 15 of a 28-day cycle. The cycles can be repeated every 28 days as long as the patient is still benefiting from and tolerating the treatment.

Romidepsin has been studied for its cytotoxic effects in various human cancer cell lines, such as leukemia, lymphoma, renal, colon, stomach, lung, ovarian, and prostate cancer cell lines.

Introduction: Romidepsin, a newly approved treatment for cutaneous T-cell lymphoma (CTCL), is a unique inhibitor of histone deacetylase (HDAC).

In 2009, the U.S. FDA granted approval for the use of Romidepsin in patients diagnosed with cutaneous T-cell lymphoma (CTCL).

Pharmac has been informed by the supplier of lomustine (marketed as CeeNU) that they will no longer be producing the medication worldwide. Lomustine is an oral anti-cancer drug commonly used in combination with chemotherapy for individuals suffering from glioma, a form of brain cancer.

BeiGene Ireland Ltd is the applicant for this medicinal product. Zanubrutinib received approval for medical use in the European Union in November 2021.

On May 15, 2020, the FDA granted accelerated approval to rucaparib (RUBRACA; Clovis Oncology, Inc., Boulder, CO) as a PARP enzyme inhibitor for treating adults with deleterious BRCA mutation (germline and/or somatic)€associated cancer.

In July 2014, the FDA granted accelerated approval to idelalisib as a standalone treatment for relapsed FL and SLL after two lines of therapy.

Romidepsin injection is prescribed for individuals who have previously undergone treatment with at least one other medication and are suffering from cutaneous T-cell lymphoma (CTCL), a collection of immune system cancers that initially manifest as skin rashes. This medication belongs to a category of drugs known as histone deacetylase (HDAC) inhibitors.

The suggested amount of romidepsin to be given is 14 mg/m2 through an intravenous route, to be administered over a span of 4 hours. This should be done on days 1, 8, and 15 of a 28-day cycle.

Cyclophosphamide, sold under the brand name Cytoxan®, is a chemotherapy drug used to inhibit the growth of cancer cells in the body. It is commonly prescribed for the treatment of lymphoma, myeloma, leukemia, breast cancer, and ovarian cancer. This medication is administered through injection or infusion by a healthcare professional in a hospital or clinic setting.

Belonging to the group of alkylating agents, cyclophosphamide is utilized to impede or halt the proliferation of cancer cells in the body during cancer treatment. In the case of nephrotic syndrome treatment, cyclophosphamide functions by suppressing the immune system of the body.

Romidepsin inhibits histone deacetylases, preventing cancer cells from dividing. Parsaclisib, on the other hand, is a PI3K inhibitor that targets the pathway responsible for promoting cancer cell proliferation, growth, and survival.

The trial of Romidepsin (Istodax, Depsipeptide, FK228) showed a response rate of 34%, which included 4 complete responses, 20 partial responses, and 26 instances of disease stabilization.

Romidepsin, marketed as Istodax, is a medication used to treat cutaneous T-cell lymphoma (CTCL) and other types of peripheral T-cell lymphomas (PTCLs). It is an anticancer agent.

Chemistry and Mechanism of Action: Romidepsin functions as a HDAC inhibitor, targeting the enzyme HDAC. HDAC is responsible for removing acetyl groups from acetylated lysine residues in histones. By inhibiting HDAC, romidepsin modulates gene expression, leading to cell cycle arrest and apoptosis.

1. Combination of ipilimumab and nivolumab is recommended for patients with intermediate or poor-risk disease.
2. Pembrolizumab in combination with axitinib is another treatment option.
3. Pembrolizumab combined with lenvatinib is also a recommended treatment approach.
4. Nivolumab in combination with cabozantinib is another effective treatment option.
5. Radical nephrectomy is recommended for patients with T4, M0 lesions.

Everolimus, also known as Afinitor, is prescribed for the treatment of advanced kidney cancers that have not responded to previous medications like sorafenib or sunitinib. It can be used alone or in combination with lenvatinib, after trying at least one other treatment. Everolimus is taken orally once a day in the form of a pill.